PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $642,280 | +6.6% | 38,506 | +76.6% | 0.00% | – |
| Q2 2023 | $602,365 | -53.4% | 21,809 | -61.2% | 0.00% | -100.0% |
| Q1 2023 | $1,292,968 | +112.0% | 56,216 | +0.6% | 0.00% | – |
| Q4 2022 | $609,770 | +600.9% | 55,891 | +443.2% | 0.00% | – |
| Q3 2022 | $87,000 | -71.0% | 10,289 | -72.9% | 0.00% | – |
| Q2 2022 | $300,000 | -58.7% | 37,956 | +23.6% | 0.00% | – |
| Q1 2022 | $727,000 | -81.5% | 30,700 | -73.2% | 0.00% | -100.0% |
| Q4 2021 | $3,922,000 | +282.6% | 114,696 | +98.3% | 0.00% | – |
| Q3 2021 | $1,025,000 | +251.0% | 57,854 | +299.7% | 0.00% | – |
| Q4 2020 | $292,000 | +12.7% | 14,473 | +9.1% | 0.00% | – |
| Q3 2020 | $259,000 | +197.7% | 13,268 | +2.5% | 0.00% | – |
| Q2 2018 | $87,000 | -62.5% | 12,945 | +18.1% | 0.00% | -100.0% |
| Q3 2016 | $232,000 | – | 10,964 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |